IDEXX LABORATORIES INC

Explore IDEXX Laboratories’ 4‑Nov 2026 Rule 144 filings: insider sales, compliance, and what they signal for investor confidence in the healthcare diagnostics sector.

UBS lowers its outlook for IDEXX Laboratories, citing regulatory tightening, fierce competition, and supply‑chain volatility. Despite solid growth, the bank warns of margin pressure and urges investors to weigh risks against AI‑driven growth opportu…